On April 15, 2025, Oak Hill Bio, a biotechnology company focused on acquiring and developing life-changing rare disease therapeutics, entered into an exclusive license agreement with Roche to obtain global rights for rugonersen (RO7248824). Rugonersen is an ASO designed as a potential best-in-class treatment for individuals with Angelman syndrome, a rare, genetic neurodevelopmental condition for which there is no approved disease-modifying treatment. Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction.

Angelman syndrome impacts approximately 500,000 people globally, leading to significant cognitive and physical challenges. Rugonersen has shown promising results in previous studies, indicating potential improvements in cognitive and developmental functions for affected individuals. Oak Hill Bio plans to initiate a Phase 3 study in early 2026.

The Wilson Sonsini team that advised Oak Hill Bio on patent matters related to the transaction includes Laurie McNamara, Tina Hanson, Minyoung Shin, Sean Reed, and Khailee Marischuk.

For more information, please see Oak Hill Bio's news release. Additional coverage can be found on The Pharma Letter and Endpoints News.